RT Journal Article
SR Electronic
T1 Recommendations for standardized management of CML patients in the core epidemic area of COVID-19 ——Multi-center survey results in Hubei Province, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.12.20034876
DO 10.1101/2020.03.12.20034876
A1 Danyu wang
A1 Jing-Ming Guo
A1 Zhuang-Zhi Yang
A1 Yong You
A1 Zhi-Chao Chen
A1 Shi-Ming Chen
A1 Hui Cheng
A1 You-Shan Zhang
A1 Dao-Zi Jiang
A1 Xue-Lan Zuo
A1 Xiao-Jian Zhu
A1 Jun Huang
A1 Hong-Xiang Wang
A1 Qing Li
A1 Qing Wu
A1 Zhi-Ping Huang
A1 Qi-Huan Liu
A1 Ying Bao
A1 Da-Lin Zhang
A1 Xin-Hua Zhang
A1 Zhe Zhao
A1 Ren-Ying Ge
A1 Jie Du
A1 Ya-Ping Wang
A1 Hong-Bo Ren
A1 Hong Han
A1 Yun-Hui Wei
A1 Hang Xiang
A1 Chu-Cheng Wan
A1 You-Fang Zhao
A1 Bin Chen
A1 Guo-Ling Yuan
A1 Meng Li
A1 Wei-ming Li
YR 2020
UL http://medrxiv.org/content/early/2020/03/16/2020.03.12.20034876.abstract
AB Background Since late December 2019, the outbreak of the novel coronavirus disease, COVID-19, that began in Wuhan, has become endemic in China and more than 100 countries and regions in the world. There is no report about the prevalence of COVID-19 in CML patients untill now. We aimed to describe the clinical course, outcomes of CML patients with COVID-19 and prevalence of COVID-19 in CML patients.Methods In this multi-center survey, cross-sectional survey, observational study, the clinical data of CML patients with COVID-19 in each center were collected. Simultaneously, an online survey was conducted for information about the CML patients under the management at each center by asking the CML patients to complete a questionnaire,from February 15, 2020 to February 21, 2020. The questionnaire includes demographic data, place of residence, smoking status, CML diagnosis and treatment, comorbidities, combined medications, epidemiological history, symptoms(fever, cough, shortness of breath, etc) during the epidemic. Additional clinical data was collected on respondents suspected or confirmed to have COVID-19. We described and analyzed the prevalence of COVID-19 in CML patients, and focus on the clinical characteristics and outcomes of COVID-19 patients. Data were compared between the CML patients with optimal response and those with non-optimal response. The primary outcome was prevalence of COVID-19 in CML patients, as of Feb 21, 2020. Secondary outcomes included the history of epidemiology of CML patients, the clinical characteristics and outcomes of CML patients with COVID-19.Findings Of 392 respondents, 223(56.9%) were males, and 240(61.2%) were 50 years or younger. Only 10 patients took drugs irregularly due to the influence of the epidemic because of traffic control, pharmacies unable to operate normally, etc. In the history of epidemiology, there were 4 patients with definite contact with COVID-19, of which 3 were remote contact and 1 was close contact. 12 respondents had fever, cough or shortness of breath during the epidemic, 1 case (common type) was confirmed with COVID-19 and cured after treatment. 1 patient was clinically diagnosed and succumbed. 1 of 299 (0.3%) patients with an optimal response was diagnosed with COVID-19. Of the 50 patients who failed to respond to CML treatment or had a poor response, 1 patient (2%) had a clinical diagnosis of COVID-19.Interpretation While the 392 CML respondents required regular referrals to hospitals, they did not have much contact with COVID-19 patients during the outbreak. Patients who failed to achieved an optimal response to CML therapy appear more likely to have a symptomatic infection with SARS-CoV-2. Older patients with comorbidities are at increased risk of death.Funding This work was supported by grants from the National Natural Science Foundation of China(NSFC)(81873440&81700142).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Natural Science Foundation of China(NSFC)(81873440&81700142).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this artical.